Zentalis Pharmaceuticals Eyes 2026 Milestones for Ovarian Cancer Drug Azenosertib

Event summary

  • Zentalis expects DENALI Part 2a dose confirmation in 1H 2026, with topline readout by year-end.
  • ASPENOVA Phase 3 trial initiation planned for 1H 2026 to support full approval.
  • MUIR Part 2 trial evaluating azenosertib + bevacizumab in ovarian cancer ongoing.
  • $245.9M cash runway projected into late 2027.

The big picture

Zentalis is advancing azenosertib, a potentially first-in-class WEE1 inhibitor, through pivotal trials for Cyclin E1-positive platinum-resistant ovarian cancer. The company's biomarker-driven approach aims to address a significant unmet need in a subset of ovarian cancer patients. Success in these trials could position azenosertib as a non-chemotherapy, oral treatment option, potentially reshaping the ovarian cancer treatment landscape.

What we're watching

Regulatory Pathway
Whether DENALI Part 2 results will support accelerated approval for azenosertib.
Execution Risk
The pace at which Zentalis can initiate and complete the ASPENOVA Phase 3 trial.
Financial Sustainability
How long Zentalis can maintain its cash runway beyond 2027.

Related topics

Pharmaceuticals